Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 313

Results For "CARE"

3169 News Found

Zydus and TLC sign agreement to market Liposomal Amphotericin B in India
News | May 26, 2021

Zydus and TLC sign agreement to market Liposomal Amphotericin B in India

With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage


Cipla to market Roche's Antibody Cocktail in India
Policy | May 25, 2021

Cipla to market Roche's Antibody Cocktail in India

The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19


Five manufacturers get license to produce Black Fungus drug
News | May 23, 2021

Five manufacturers get license to produce Black Fungus drug

NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers


India's first indigenous COVID-19 RT-PCR testing kit approved
News | May 21, 2021

India's first indigenous COVID-19 RT-PCR testing kit approved

This kit was developed in partnership with Gujarat-based LabCare Diagnostics. LabCare is into clinical chemistry reagents, serology tests, immuno-chromatographic tests and urine analysis strips


Zydus Cadila entity to sell its India focused animal health business to a consortium
News | May 13, 2021

Zydus Cadila entity to sell its India focused animal health business to a consortium

The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,


COVAXIN phase II/III clinical trial approved for 2-18 years
News | May 13, 2021

COVAXIN phase II/III clinical trial approved for 2-18 years

BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years


Govt. ramps up Amphotericin B manufacturing to fight Mucormycosis
News | May 12, 2021

Govt. ramps up Amphotericin B manufacturing to fight Mucormycosis

The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021


Vivimed Labs to manufacture, market Favipiravir tablets
News | May 11, 2021

Vivimed Labs to manufacture, market Favipiravir tablets

The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India


DCGI approves anti-COVID drug developed by DRDO
Policy | May 10, 2021

DCGI approves anti-COVID drug developed by DRDO

The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production


Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India
News | May 10, 2021

Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India

Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)